Valuation: Cizzle Biotechnology Holdings Plc

Capitalization 59.46L 80.65L 69L 64.3L 1.1Cr 69Cr 1.23Cr 7.69Cr 2.94Cr 32Cr 3.02Cr 2.96Cr 118.1Cr P/E ratio 2023
-4.04x
P/E ratio 2024 -2.77x
Enterprise value 55.59L 75.4L 64.51L 60.11L 1.03Cr 65Cr 1.15Cr 7.19Cr 2.74Cr 30Cr 2.83Cr 2.77Cr 110.41Cr EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
56.35%
Yield 2023 *
-
Yield 2024 -
More valuation ratios * Estimated data
Dynamic Chart
1 day-2.27%
1 week-5.42%
Current month-5.42%
1 month-16.23%
3 months-5.42%
6 months-22.84%
Current year-5.42%
More quotes
1 week 1.4
Extreme 1.4
1.6
1 month 1.4
Extreme 1.4
1.8
Current year 1.3
Extreme 1.3
2.68
1 year 1.3
Extreme 1.3
2.68
3 years 1.3
Extreme 1.3
4.84
5 years 1.3
Extreme 1.3
13
10 years 1.3
Extreme 1.3
13
More quotes
Manager TitleAgeSince
Director of Finance/CFO 64 14/05/2021
Chief Tech/Sci/R&D Officer 60 02/01/2025
Director TitleAgeSince
Director/Board Member 43 29/01/2019
Chairman 68 21/05/2019
Director/Board Member 60 14/05/2021
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-2.27%-5.42%-33.36%+4.71% 80.65L
-1.07%+1.22%+10.51%-0.95% 5.04TCr
-0.90%+3.22%+73.51%+34.25% 3TCr
+1.42%+5.74%+4.18%+11.14% 2.87TCr
+2.17%+0.53%-22.30%-24.53% 2.86TCr
-0.23%-0.88%+26.66%-22.32% 1.27TCr
+1.02%+1.31%-53.73%-30.23% 1.21TCr
+0.44%+1.33%+28.51%+88.54% 1.07TCr
+1.23%-0.19%+17.83%-5.21% 1.05TCr
+2.04%-2.25%+70.29% - 1.03TCr
Average +0.20%-0.96%+12.21%+6.16% 1.94TCr
Weighted average by Cap. +0.27%-0.58%+16.09%+4.57%
See all sector performances

Financials

2023 2024
Net sales - -
Net income -17.17L -23.29L -19.93L -18.57L -31.87L -20Cr -35.48L -2.22Cr -84.78L -9.33Cr -87.33L -85.54L -34Cr -21.66L -29.38L -25.14L -23.42L -40.2L -25Cr -44.76L -2.8Cr -1.07Cr -12Cr -1.1Cr -1.08Cr -43Cr
Net Debt -15.57L -21.12L -18.07L -16.84L -28.9L -18Cr -32.18L -2.01Cr -76.88L -8.46Cr -79.2L -77.57L -31Cr -4L -5L -4L -4L -7L -4.5Cr -8L -50.04L -19.11L -2.1Cr -19.68L -19.28L -7.69Cr
More financial data * Estimated data
Logo Cizzle Biotechnology Holdings Plc
Cizzle Biotechnology Holdings Plc is a United Kingdom-based diagnostics development company. The Company is engaged in the development of a blood test for the early detection of lung cancer. Its prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a cell nuclear protein involved in deoxyribonucleic acid (DNA) replication, and the targeted CIZ1B variant is correlated with early-stage lung cancer. Its prototype confirmative test has been developed to address the false positive rates of computed tomography (CT) scanning. The test is intended to address a clear unmet clinical need, which is early detection of lung cancer, when curative surgical resection is possible.
Employees
4
More about the company
Date Price Change Volume
11/25/11 1.466 p -2.27% 67,527
10/25/10 1.500 p 0.00% 4,03,377
09/25/09 1.500 p 0.00% 2,19,964
08/25/08 1.500 p 0.00% 87,988
07/25/07 1.500 p 0.00% 1,72,428

Delayed Quote London S.E., July 11, 2025 at 03:00 pm IST

More quotes